Becodefence, Plus Nasal Spray – Gets to Work in 3 Minutes NonDrowsy 120 Sprays, 20 ml

Product Information

Simons FE, Simons KJ. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999;36(5):329-52. Benzalkonium chloride may cause irritation or swelling inside the nose, especially if used for a long period of time. If your doctor has prescribed high doses of mometasone, or you’re also taking other steroid medicines or tablets for fungal infections or HIV, you may get underactive adrenal glands as a side effect. Ask your doctor if you need to carry a steroid emergency card. Common side effects

The recommended dosage is two sprays into each nostril twice daily (400 micrograms/day). Once control has been established it may be possible to maintain control with fewer sprays. A dosage regimen of one spray into each nostril morning and evening has been shown to be efficacious in some patients. However, should symptoms recur, patients should revert to the recommended dosage of two sprays into each nostril morning and evening. The minimum dose should be used at which effective control of symptoms is maintained. Total daily administration should not normally exceed eight sprays. If you forget to take a dose, use it as soon as you remember. Unless it's almost time for your next dose, in which case skip the missed dose and take your next one as usual. If you're prescribed beclometasone, your doctor may advise you to use it for longer. If you forget to use itTo use the spray, first remove the safety clip and plastic cap. Close one nostril by pressing it with your finger. Tilt your head slightly forward and, keeping the bottle upright, carefully insert the nasal applicator into the other nostril. Press down firmly on the pump to deliver the prescribed number of sprays. Do not spray directly onto the middle wall of your nose ( nasal septum). Breathe in gently through your nose and out through your mouth. Repeat in the other nostril. Wipe the applicator tip and replace the plastic cap and safety clip. Avoid blowing your nose for 15 minutes after using this medication. Tell your doctor right away if you have any serious side effects, including: loss of taste or smell, pain/sores in your nose. During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

Follow the instructions that come with your medicine. Do not use more than 4 sprays per nostril in 24 hours. Changes to your dose Beconase AQ can affect growth in children. Talk with your doctor if you think your child is not growing at a normal rate while using Beconase AQ. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/ tongue/throat), severe dizziness, wheezing/ trouble breathing. BDP is cleared very rapidly from the circulation and plasma concentrations are undetectable (< 50pg/ml) following oral or intranasal dosing. There is rapid metabolism of the majority of the swallowed portion of BDP during its first passage through the liver. The main product of metabolism is the active metabolite (B-17-MP). Minor inactive metabolites, beclometasone-21-monopropionate (B-21-MP) and beclometasone (BOH), are also formed but these contribute little to systemic exposure. You'll usually use the spray twice a day, once in the morning and once at night. The usual dose is 1 or 2 sprays into each nostril.Care must be taken while transferring patients from systemic steroid treatment to Beconase Aqueous Nasal Spray if there is any reason to suppose that their adrenal function is impaired. changes in your eyesight, such as blurred vision or a cloudy lens in the eye – these can be signs of increased pressure in your eyes ( glaucoma) or a cataract Following intranasal administration of BDP in healthy males, the systemic absorption was assessed by measuring the plasma concentrations of its active metabolite B-17-MP, for which the absolute bioavailability following intranasal administration is 44% (95% CI 28%, 70%). After intranasal administration, <1% of the dose is absorbed by the nasal mucosa. The remainder after being cleared from the nose, either by drainage or mucocilary clearance, is available for absorption from the gastrointestinal tract. Plasma B-17-MP is almost entirely due to conversion of BDP absorbed from the swallowed dose. Del Cuvillo A, Mullol J, Bartra J, Dvila I, Juregui I, Montoro J, Sastre J, Valeron AL. Comparative pharmacology of the H1 antihistamines. J Invest Alergol Clin Immunol 2006;16(S1):3-12. If you're using a new bottle, it may not work first time. Pump the spray a few times until a fine mist comes out. You'll also need to do this if you have not used the bottle for a few days.